(Abstracted from Int Urogynecol J 2016; DOI 10.1007/s00192-016-3219-x)
Oral antimuscarinic agents have been the criterion standard of pharmacotherapy for the treatment of overactive bladder (OAB) symptoms for several decades. Mirabegron, a selective β3-adrenergic receptor agonist, represents a new class of drugs for OAB with proven efficacy, good safety, and tolerability.
Department of Obstetrics and Gynecology, University of Insubria, Varese (M.S., P.S., S.C., F.G.); Academic Unit of Obstetrics and Gynaecology, IRCCS AOU San Martino—IST (U.L.R.M.); Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa (U.L.R.M.), Genoa; and Department of Experimental Medicine and Surgery, University Tor Vergata, Rome (E.F.A.), Italy